Medtronic reported Q3 fiscal 2026 revenue of $9.0 billion, exceeding analyst estimates of $8.89 billion, marking its highest revenue growth in 10 quarters. The medical technology giant achieved 8.7% reported growth and 6.0% organic growth year-over-year, with adjusted earnings per share of $1.36 surpassing the $1.34 consensus. The Cardiovascular Portfolio led the charge, surging 13.8% as reported and 10.6% organically to $3.46 billion, driven by Cardiac Ablation Solutions' 80% global and 137% U.S. growth. Geoff Martha, CEO, emphasized the portfolio's strength, citing new market expansion and high-growth investments.

Other segments, including Neuroscience ($2.56 billion) and Diabetes ($796 million), also outperformed, with the latter rising 14.8%. The company maintained its fiscal 2026 guidance, projecting 5.5% organic growth and $5.62–$5.66 EPS, despite potential $185 million tariff impacts. Medtronic's performance underscores resilience in a competitive medical tech landscape, with its Cardiac Ablation Solutions segment emerging as a key growth driver.